BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 3611859)

  • 1. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
    Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM
    Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
    Katoch K; Natarajan M; Bagga A; Katoch VM
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
    Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two multidrug regimens in multibacillary leprosy.
    Jadhav VH; Patki AH; Mehta JM
    Indian J Lepr; 1992; 64(4):501-4. PubMed ID: 1308526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
    Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
    Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hansen's disease in Portugal: multibacillary patients treated between 1988 and 2003.
    Medeiros S; Catorze MG; Vieira MR
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):29-35. PubMed ID: 18713227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Bhatia AS; Sreevatsa ; Gupta UD; Sharma VD; Shivannavar CT; Patil MA; Bharadwaj VP
    Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):202-12. PubMed ID: 7602215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three years assessment of multidrug therapy in multibacillary leprosy cases.
    Ganapati R; Revankar CR; Pai RR
    Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short term combination therapy for paucibacillary leprosy--histological evaluation & follow-up study.
    Kumar B; Kaur S; Kaur I
    Indian J Lepr; 1987; 59(1):54-62. PubMed ID: 3302061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of short term results in two multidrug regimens in multibacillary leprosy.
    Singh RP; Tiwari VD; Chattopadhyay SP
    Indian J Lepr; 1993; 65(2):173-80. PubMed ID: 8345231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with multidrug therapy in paucibacillary leprosy.
    Bhate RD; Gupta CM; Chattopadhyay SP; Singh IP
    Indian J Lepr; 1986; 58(2):244-50. PubMed ID: 3805797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of three-year multidrug therapy in multibacillary leprosy patients.
    Li W; Ye G; Yang Z; Tao M; Luo J; Wang C; Ji F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):37-40. PubMed ID: 2371263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.